Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | ABL2 | P42684 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658825 | 1.00 | SRC (0.49) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL28685316 | 0.85 | DYRK1A (0.44) | SRCEGFRMAP4K4LRRK2 | |
| SCHEMBL22658694 | 0.83 | LRRK2 (0.43) | EGFRLRRK2 | |
| SCHEMBL29407749 | 0.83 | LRRK2 (0.43) | EGFRLRRK2 | |
| SCHEMBL29407628 | 0.83 | SRC (0.52) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL22658709 | 0.83 | SRC (0.52) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL22676717 | 0.79 | SRC (0.52) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL22677043 | 0.77 | F13A1 (0.45) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL869280 | 0.76 | SRC (0.64) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL19476297 | 0.76 | JAK2 (0.66) | SRCEGFRABL1ABL2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114126620-B | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-3968999-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114126620-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2022-03-01 | — | — | CN | disclosed |